181 related articles for article (PubMed ID: 35908410)
1. Sensitization of cancer cells towards Cisplatin and Carboplatin by protein kinase D inhibitors through modulation of ATP7A/B (copper transport ATPases).
Janardhanan P; Somasundaran AK; Balakrishnan AJ; Pilankatta R
Cancer Treat Res Commun; 2022; 32():100613. PubMed ID: 35908410
[TBL] [Abstract][Full Text] [Related]
2. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells.
Samimi G; Safaei R; Katano K; Holzer AK; Rochdi M; Tomioka M; Goodman M; Howell SB
Clin Cancer Res; 2004 Jul; 10(14):4661-9. PubMed ID: 15269138
[TBL] [Abstract][Full Text] [Related]
3. Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B.
Samimi G; Katano K; Holzer AK; Safaei R; Howell SB
Mol Pharmacol; 2004 Jul; 66(1):25-32. PubMed ID: 15213293
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin sensitivity of oral squamous carcinoma cells is regulated by Na+,K+-ATPase activity rather than copper-transporting P-type ATPases, ATP7A and ATP7B.
Ahmed Z; Deyama Y; Yoshimura Y; Suzuki K
Cancer Chemother Pharmacol; 2009 Mar; 63(4):643-50. PubMed ID: 18545997
[TBL] [Abstract][Full Text] [Related]
5. Annexin A4-conferred platinum resistance is mediated by the copper transporter ATP7A.
Matsuzaki S; Enomoto T; Serada S; Yoshino K; Nagamori S; Morimoto A; Yokoyama T; Kim A; Kimura T; Ueda Y; Fujita M; Fujimoto M; Kanai Y; Kimura T; Naka T
Int J Cancer; 2014 Apr; 134(8):1796-809. PubMed ID: 24150977
[TBL] [Abstract][Full Text] [Related]
6. Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients.
Samimi G; Varki NM; Wilczynski S; Safaei R; Alberts DS; Howell SB
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5853-9. PubMed ID: 14676106
[TBL] [Abstract][Full Text] [Related]
7. Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells.
Kalayda GV; Wagner CH; Buss I; Reedijk J; Jaehde U
BMC Cancer; 2008 Jun; 8():175. PubMed ID: 18565219
[TBL] [Abstract][Full Text] [Related]
8. Involvement of protein kinase D in expression and trafficking of ATP7B (copper ATPase).
Pilankatta R; Lewis D; Inesi G
J Biol Chem; 2011 Mar; 286(9):7389-96. PubMed ID: 21189263
[TBL] [Abstract][Full Text] [Related]
9. Role of copper transporters in resistance to platinating agents.
Rabik CA; Maryon EB; Kasza K; Shafer JT; Bartnik CM; Dolan ME
Cancer Chemother Pharmacol; 2009 Jun; 64(1):133-42. PubMed ID: 18998134
[TBL] [Abstract][Full Text] [Related]
10. Translocation of platinum anticancer drugs by human copper ATPases ATP7A and ATP7B.
Tadini-Buoninsegni F; Bartolommei G; Moncelli MR; Inesi G; Galliani A; Sinisi M; Losacco M; Natile G; Arnesano F
Angew Chem Int Ed Engl; 2014 Jan; 53(5):1297-301. PubMed ID: 24375922
[TBL] [Abstract][Full Text] [Related]
11. miR-495 enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of copper-transporting P-type adenosine triphosphatase A (ATP7A).
Song L; Li Y; Li W; Wu S; Li Z
J Cell Biochem; 2014 Jul; 115(7):1234-42. PubMed ID: 24038379
[TBL] [Abstract][Full Text] [Related]
12. Sec61β controls sensitivity to platinum-containing chemotherapeutic agents through modulation of the copper-transporting ATPase ATP7A.
Abada PB; Larson CA; Manorek G; Adams P; Howell SB
Mol Pharmacol; 2012 Sep; 82(3):510-20. PubMed ID: 22710939
[TBL] [Abstract][Full Text] [Related]
13. Functional interactions of Cu-ATPase ATP7B with cisplatin and the role of ATP7B in the resistance of cells to the drug.
Leonhardt K; Gebhardt R; Mössner J; Lutsenko S; Huster D
J Biol Chem; 2009 Mar; 284(12):7793-802. PubMed ID: 19141620
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of tumor resistance to cisplatin mediated by the copper transporter ATP7B.
Dmitriev OY
Biochem Cell Biol; 2011 Apr; 89(2):138-47. PubMed ID: 21455266
[TBL] [Abstract][Full Text] [Related]
15. Activity and Trafficking of Copper-Transporting ATPases in Tumor Development and Defense against Platinum-Based Drugs.
Petruzzelli R; Polishchuk RS
Cells; 2019 Sep; 8(9):. PubMed ID: 31540259
[TBL] [Abstract][Full Text] [Related]
16. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.
Samimi G; Howell SB
Cancer Chemother Pharmacol; 2006 Jun; 57(6):781-8. PubMed ID: 16170571
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of charge transfer in human copper ATPases ATP7A and ATP7B.
Tadini-Buoninsegni F; Smeazzetto S
IUBMB Life; 2017 Apr; 69(4):218-225. PubMed ID: 28164426
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Targeting of ATP7B in Ovarian Carcinoma.
Mangala LS; Zuzel V; Schmandt R; Leshane ES; Halder JB; Armaiz-Pena GN; Spannuth WA; Tanaka T; Shahzad MM; Lin YG; Nick AM; Danes CG; Lee JW; Jennings NB; Vivas-Mejia PE; Wolf JK; Coleman RL; Siddik ZH; Lopez-Berestein G; Lutsenko S; Sood AK
Clin Cancer Res; 2009 Jun; 15(11):3770-80. PubMed ID: 19470734
[TBL] [Abstract][Full Text] [Related]
19. Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines.
Kitada N; Takara K; Minegaki T; Itoh C; Tsujimoto M; Sakaeda T; Yokoyama T
Cancer Chemother Pharmacol; 2008 Sep; 62(4):577-84. PubMed ID: 18030470
[TBL] [Abstract][Full Text] [Related]
20. Copper-transporting P-type ATPase, ATP7A, confers multidrug resistance and its expression is related to resistance to SN-38 in clinical colon cancer.
Owatari S; Akune S; Komatsu M; Ikeda R; Firth SD; Che XF; Yamamoto M; Tsujikawa K; Kitazono M; Ishizawa T; Takeuchi T; Aikou T; Mercer JF; Akiyama S; Furukawa T
Cancer Res; 2007 May; 67(10):4860-8. PubMed ID: 17510416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]